Cartalax (Bioregulator)

Cartalax is a synthetic tripeptide (Ala-Glu-Asp) belonging to the Khavinson class of bioregulatory peptides. It is designed to target cartilage and musculoskeletal tissue through proposed peptide-DNA interactions that modulate chondrocyte gene expression. Developed at the Saint Petersburg Institute of Bioregulation and Gerontology, Cartalax follows the bioregulatory model proposing that short peptides can penetrate cells and interact with specific DNA sequences to influence tissue-specific transcription. Cartalax has been investigated in Russian biogerontology research in the context of cartilage maintenance, chondrocyte biology, and age-related changes in articular tissue. As a tripeptide, it represents one of the shortest sequences in the Khavinson bioregulator family, reflecting the hypothesis that even minimal peptide sequences can carry tissue-targeting information through their charge distribution and spatial conformation.

Cartalax has been investigated for its proposed interactions with gene regulatory elements in chondrocytes and cartilage tissue cells. The Khavinson model proposes that the Ala-Glu-Asp sequence can penetrate cell membranes and interact with DNA in promoter regions of genes involved in cartilage matrix synthesis and maintenance. Researchers have studied Cartalax for its potential effects on expression of collagen type II, aggrecan, and other extracellular matrix components that define cartilage tissue identity. In preclinical chondrocyte culture models, investigators observed changes in matrix protein expression and proliferation markers following Cartalax treatment. Studies from the Saint Petersburg group suggest that bioregulatory peptides targeting cartilage may influence the balance between matrix synthesis and degradation by modulating expression of both structural proteins and matrix-degrading enzymes. These effects are attributed to epigenetic gene regulation rather than conventional receptor-mediated signaling pathways.

Chondrocyte Studies

Khavinson et al. (2009) investigated short peptides including Cartalax in chondrocyte culture models. Researchers observed changes in matrix protein expression and cell proliferation markers following treatment with the tripeptide [1].

Bioregulatory Peptide Framework

Khavinson VK (2002) described the theoretical and experimental basis for tissue-specific bioregulatory peptides, including those targeting musculoskeletal tissues, in a comprehensive review of the field [2].

Peptide Epigenetics

Khavinson et al. (2014) reviewed the evidence for short peptide regulation of gene expression through epigenetic mechanisms, including histone modifications and chromatin remodeling associated with bioregulatory peptide treatment in various tissue models [3].